STATISTICAL SUMMARY
Research
Dr. Lodder has conducted research using grants totaling over
$18 million. This research led to commercialization via ten patents,
four additional pending patent applications, the founding of two
new companies, and a NASDAQ company. The first start-up company,
InfraReDx, was founded in 1998 and has raised $40 million in private
capital for new research. InfraReDx is headquartered in Cambridge,
Massachusetts. The second company, Prescient, has raised $27 million
for research and development. The total of $67 million in venture
capital goes toward meeting the state mandate to commercialize
university research. Prescient is in Doylestown, PA, and Boston,
MA. Dr. Lodder serves as president and is on the board of directors of
Spherix (NASDAQ:
SPEX). In addition, Dr. Lodder conducts joint research with a
DoD contractor, SESI, which received $2.7 million in their DARPA/NIH
contract to produce PRM solid-state laser systems for remote sensing.
Dr. Lodder is author of 94 publications and over 250 presentations.
The Chemical Abstracts Service indexes 89 publications, while
22 are indexed by PubMed. The Web of Science citation index lists
684 papers that cite Dr. Lodder's research (an average of over
7 citations/publication). Dr. Lodder is the recipient of two national
and five international research achievement awards totaling $35,000
in prizes.
Dr. Lodder's doctoral graduates have entered academia (e.g., James
K. Drennen, III, Ph.D., now chair of Pharmaceutical Sciences at
Duquesne University), government (e.g., Wm. Charles Symons, Ph.D.,
who has a top secret clearance in his position at the Engineering
Research Center at the Federal Bureau of Investigation), and industry
(e.g., Robert G. Buice, Jr., Ph.D., Manager, Technical Services,
Chattem Pharmaceuticals).
Teaching
Dr. Lodder's teaching is demonstrated
not only by teaching evaluations, but also in external evaluations
of his course web products submitted by scientists worldwide (for
PHR 510, CHE 626 and CHE 522), by the public at large (who use
the guide to Home Diagnostic Kits created by PHR 895 about 15,000
times each day), and by peer-reviewed publication of the term
papers written as lab reports for his courses.
Service
Dr. Lodder has served on several
NIH study sections and has been invited to NSF, NIH and DARPA
workshops. He was appointed by the Food and Drug Administration
to serve on their Process Analytical Technologies (PAT) subcommittee,
which aims to revolutionize the pharmaceutical industry by replacing
the GMP standards under which drugs have been released for the
past 40 years with new, science-based PAT methods. He has recently
begun working with the U.S. Pharmacopoeia in this capacity as
well. Dr. Lodder has served as both chair and vice chair of the
local section of the American Chemical Society, and Treasurer
of the local AAUP. Dr. Lodder has been twice elected to the
Pharmaceutical
Sciences Executive Committee by the division faculty. While in
the College of Pharmacy, he also serves the university through
affiliations with the Chemistry Department, Department of Electrical
and Computer Engineering, Center for Computational Sciences, Graduate
Center for Nutritional Sciences, and Gill Heart Institute.